KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2025)

Aurinia Pharmaceuticals' Gross Margin history spans 6 years, with the latest figure at 88.59% for Q4 2025.

  • For Q4 2025, Gross Margin fell 214.0% year-over-year to 88.59%; the TTM value through Dec 2025 reached 88.46%, up 47.0%, while the annual FY2025 figure was 88.46%, 47.0% up from the prior year.
  • Gross Margin reached 88.59% in Q4 2025 per AUPH's latest filing, roughly flat from 88.87% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 98.82% in Q1 2022 to a low of 84.42% in Q2 2024.
  • Average Gross Margin over 5 years is 92.27%, with a median of 92.71% recorded in 2024.
  • Peak YoY movement for Gross Margin: crashed -1419bps in 2024, then surged 541bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 97.94% in 2021, then fell by -3bps to 95.21% in 2022, then dropped by -8bps to 88.04% in 2023, then increased by 3bps to 90.73% in 2024, then dropped by -2bps to 88.59% in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Gross Margin are 88.59% (Q4 2025), 88.87% (Q3 2025), and 89.84% (Q2 2025).